Cell Therapy News

A new retrospective analysis has added to building evidence that suggests chimeric antigen receptor T-cell therapy does not directly cause secondary malignancies.

Healio will present its fourth annual Disruptive Innovators Awards for oncology/hematology this spring.

Satricabtagene autoleucel improved PFS compared with physician’s choice of therapy for patients with Claudin18.2 expression-positive advanced gastric or gastroesophageal junction cancers, according to the agent’s manufacturer.

SAN DIEGO — Anitocabtagene autoleucel exhibited durable efficacy among heavily pretreated patients with high-risk relapsed or refractory multiple myeloma, results of the phase 2 iMMagine-1 study showed.

It’s only the beginning.

SAN DIEGO — Tabelecleucel provided durable benefit to solid organ or allogeneic hematopoietic cell transplant recipients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease, according to study results.

SAN DIEGO — Patients underrepresented in pivotal trials of anti-CD19 chimeric antigen receptor T-cell therapy may still derive benefit from the treatment modality, according to a speaker at ASH Annual Meeting and Exposition.

SAN DIEGO — A ketogenic diet may improve antitumor function through beta-hydroxybutyrate, according to early research presented in a plenary scientific session at the ASH Annual Meeting and Exposition.

SAN DIEGO — A new chimeric antigen receptor T-cell therapy option made in less than a day may be a new option for patients with relapsed/refractory non-Hodgkin lymphoma, according to research presented at ASH Annual Meeting and Exposition.